Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

161
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
161
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

560
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
560
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

456
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
456
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

40
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
40
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

296
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
296
Factors Affecting Drug Distribution: Miscellaneous Factors01:19

Factors Affecting Drug Distribution: Miscellaneous Factors

669
Drug distribution in the human body is a complex process influenced by various individual factors, including age, pregnancy, obesity, diet, body water composition, pH levels, and specific disease conditions.
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...
669
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 心血管疾患の患者における薬物相互作用とその関連因子の評価:占領下のパレスチナ地域における横断的な研究

心血管疾患の患者における薬物相互作用とその関連因子の評価:占領下のパレスチナ地域における横断的な研究

Samah W Al-Jabi1, Lama Aldabe2, Lina Alhaj-Asaad2

  • 1Division of Clinical and Community Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, occupied Palestinian territory.

Lancet (London, England)
|July 6, 2021

関連する実験動画

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

786
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.0K

PubMed で要約を見る

まとめ
この要約は機械生成です。

潜在的な薬物相互作用 (pDDI) の高い流行は,西岸の心血管疾患 (CVD) の患者で発見されました. これらの相互作用は病気や薬の数と関連しており, 薬剤師の意識と関与の必要性を強調しています.

科学分野:

  • 薬理学について
  • 心臓病科
  • 公衆衛生

背景:

  • 心血管疾患 (CVD) は世界の主要な死因です.
  • 潜在的薬物相互作用 (pDDI) は薬剤の副作用,罹病率,および死亡率に大きく寄与する.
  • 複雑な状態と治療法を持つCVD患者は,pDDIの注意深い監視を必要とします.

研究 の 目的:

  • 心血管疾患患者のpDDIの流行と種類を決定する.
  • この患者集団におけるpDDIに関連した要因を特定する.

主な方法:

  • 西岸北部の2つの紹介病院で横断的な研究が行われました.
  • 医療記録とインタビューを通じて,CVDと診断された400人の入院患者からデータを収集した.
  • 潜在的薬物相互作用 (pDDI) は,放出薬のLexicomp相互作用チェックを使用して特定されました.

主要な成果:

  • 94%の患者 (375/400) は,pDDIを含む薬剤で退院しました.
  • 患者は平均で3. 14の病気と7. 08の薬を服用した. 併発性疾患には糖尿病と慢性腎臓病が含まれていた.
  • よくあるpDDIは,アスピリンとフロセミドまたはACE阻害剤,およびスタチンとプロトンポンプ阻害剤を併用したものです.

関連する実験動画

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

786
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.0K

結論:

  • CVD患者におけるpDDIの高い罹患率は,定期的なモニタリングを必要とします.
  • 病気が多くなり,薬が多くなり,入院時間が長くなり,PDDIが多くなる.
  • PDDIに関連するリスクを予防するには,意識を高め,臨床薬剤師を薬剤レビューに巻き込むことが不可欠です.